IP Library Granted Patent US 10,317,395
Granted Patent B1
US 10,317,395 · App. 15/253,078 · Granted Jun 11, 2019

Ex vivo engineered immune organoids for controlled germinal center reactions

Inventors: Ankur Singh (Ithaca, NY); Alberto Purwada (Ithaca, NY)
Assignee: Cornell University
G01N33/5088C07K16/00G01N2333/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,317,395
App. No.
15/253,078
Granted
Jun 11, 2019
Kind
B1
Abstract

Provided are compositions and methods that relate ex vivo organoids that contain B cells and stromal cells in a three dimensional material includes a hydrogel. The hydrogel can be formed without exposure to ultraviolet light from an electronic ultraviolet light source. The hydrogel contains silicate nanoparticles (SiNPs) that are ionically bonded to a polyampholytic gelatin. The three dimensional material can be held at a temperature of at least 37 degrees Celsius and does not liquefy. The organoids exhibit mechanical properties that are similar to certain lymphoid tissues, and can include a germinal center. Methods of making the organoids are included, as are high throughput screening approaches that use the organoids for screening a variety of test agents. The organoids can synthesize a variety of compounds that can be recovered from the organoids or the organoid culture medium.

Claims (4)

1. An ex vivo organoid comprising B cells and stromal cells in a three dimensional material, wherein the B cells are naïve B cells, primary B cells, or a combination thereof, wherein the three dimensional material comprises a hydrogel, wherein the hydrogel is formed without exposure to ultraviolet light from an electronic ultraviolet light source, and wherein the hydrogel comprises about 1.5% silicate nanoparticles (SiNPs) that are in physical association with about 2% polyampholytic gelatin, and wherein at day 4 the organoid comprises at least 10× more CD19+ cells relative to a control organoid that does not contain about 1.5% SiNPs and about 2% polyampholytic gelatin.

2. The organoid of claim 1 , wherein the physical association comprises SiNPs that are ionically bonded to the polyampholytic gelatin.

3. The organoid of claim 1 , wherein the organoid is at a temperature of at least 37 degrees Celsius and the three dimensional material is not liquefied.

4. The organoid of claim 1 , wherein the organoid is in contact with one or more growth factors, one or more cytokines, one or more extracellular matrix (ECM) ligands, or combinations thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: SINGH, ANKUR; PURWADA, ALBERTO
To: CORNELL UNIVERSITY
Reel/Frame 040191/0832 →
CONFIRMATORY LICENSE Recorded Oct 3, 2016
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040204/0391 →
Continuity (1)
Provisional Application 62212435 · Aug 31, 2015
Cited By (1)
US 12,685,804